faricimab

Details

Files

Generic Name:

faricimab

Project Status:

Complete

Therapeutic Area:

Diabetic Macular Edema

Manufacturer:

Hoffmann-La Roche Canada

Brand Name:

Vabysmo

Project Line:

Reimbursement Review

Project Number:

SR0729-000

NOC Status at Filing:

Pre NOC

Biosimilar:

Manufacturer Requested Reimbursement Criteria¹:

For the treatment of Diabetic Macular Edema (DME).

Submission Type:

Initial

Fee Schedule:

Schedule A

Tumour Type:

N/A

Indications:

For the treatment of Diabetic Macular Edema (DME).

Recommendation Type:

Reimburse with clinical criteria and/or conditions

Final Recommendation:

October 14, 2022

The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones²
Call for patient/clinician input open	February 24, 2022
Call for patient/clinician input closed	April 14, 2022
Clarification: - Patient input submission received from Fighting Blindness Canada, The Canadian Council of the Blind, CNIB, Vision Loss Rehabilitation Canada, Diabetes Canada
Submission received	March 24, 2022
Submission accepted	April 07, 2022
Review initiated	April 08, 2022
Draft CADTH review report(s) provided to sponsor for comment	June 23, 2022
Deadline for sponsors comments	July 05, 2022
CADTH review report(s) and responses to comments provided to sponsor	August 12, 2022
Expert committee meeting (initial)	August 24, 2022
Draft recommendation issued to sponsor	September 07, 2022
Draft recommendation posted for stakeholder feedback	September 15, 2022
End of feedback period	September 29, 2022
Final recommendation issued to sponsor and drug plans	October 13, 2022
Final recommendation posted	October 31, 2022
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	October 27, 2022
CADTH review report(s) posted	January 12, 2023

Last Updated : January 13, 2023